Yu Kuei Lin1,2, Bixia Gao3, Lili Liu3, Lynn Ang4, Kara Mizokami-Stout4, Rodica Pop-Busui4, Luxia Zhang5,6,7. 1. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. yuklin@med.umich.edu. 2. Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Brehm Tower 5119, 1000 Wall Street, Ann Arbor, MI, USA. yuklin@med.umich.edu. 3. Department of Medicine, Peking University First Hospital, Beijing, China. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 5. Renal Division, Department of Medicine, Peking University First Hospital, 8 Xishiku Street, Xicheng District, Beijing, 100034, China. zhanglx@bimu.eu.dn. 6. Key Laboratory of Renal Disease, National Health Commission of the People's Republic of China, Beijing, China. zhanglx@bimu.eu.dn. 7. Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China. zhanglx@bimu.eu.dn.
Abstract
PURPOSE OF REVIEW: Diabetes can lead to development of devastating microvascular complications, such as nephropathy, retinopathy, and peripheral sensory and autonomic neuropathy. While China and the USA both face the threat of this major public health challenge, the literature is limited in describing similarities and differences in the prevalence, and risk factors for the development, of diabetic microvascular complications between these two countries. RECENT FINDINGS: The current review discusses the following: (1) the most recent evidence on prevalence of diabetic microvascular complications in China and the USA (including downtrends of diabetes retinopathy and neuropathy in the USA); (2) differences in patient risk factors of these complications; (3) challenges and current knowledge gaps (such as lacking national epidemiological data of diabetic complications in China); and (4) potential future clinical and research opportunities (including needs in diabetes evaluation and management in remote areas and standardization of methods in evaluating diabetic complications across countries). Diabetic microvascular complications remain to be health threats in both China and the USA. Further investigations are needed for comprehensive understanding and effect prevention and management of these complications.
PURPOSE OF REVIEW: Diabetes can lead to development of devastating microvascular complications, such as nephropathy, retinopathy, and peripheral sensory and autonomic neuropathy. While China and the USA both face the threat of this major public health challenge, the literature is limited in describing similarities and differences in the prevalence, and risk factors for the development, of diabetic microvascular complications between these two countries. RECENT FINDINGS: The current review discusses the following: (1) the most recent evidence on prevalence of diabetic microvascular complications in China and the USA (including downtrends of diabetes retinopathy and neuropathy in the USA); (2) differences in patient risk factors of these complications; (3) challenges and current knowledge gaps (such as lacking national epidemiological data of diabetic complications in China); and (4) potential future clinical and research opportunities (including needs in diabetes evaluation and management in remote areas and standardization of methods in evaluating diabetic complications across countries). Diabetic microvascular complications remain to be health threats in both China and the USA. Further investigations are needed for comprehensive understanding and effect prevention and management of these complications.
Entities:
Keywords:
China; Diabetes; Nephropathy; Neuropathy; Retinopathy; USA
Authors: Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak Journal: Lancet Date: 2010-06-30 Impact factor: 79.321
Authors: Maryam Afkarian; Leila R Zelnick; Yoshio N Hall; Patrick J Heagerty; Katherine Tuttle; Noel S Weiss; Ian H de Boer Journal: JAMA Date: 2016-08-09 Impact factor: 56.272
Authors: Ian H de Boer; Tessa C Rue; Yoshio N Hall; Patrick J Heagerty; Noel S Weiss; Jonathan Himmelfarb Journal: JAMA Date: 2011-06-22 Impact factor: 56.272
Authors: Alice P S Kong; Gang Xu; Nicola Brown; Wing-Yee So; Ronald C W Ma; Juliana C N Chan Journal: Nat Rev Endocrinol Date: 2013-05-28 Impact factor: 43.330
Authors: Rodica Pop-Busui; Andrew J M Boulton; Eva L Feldman; Vera Bril; Roy Freeman; Rayaz A Malik; Jay M Sosenko; Dan Ziegler Journal: Diabetes Care Date: 2017-01 Impact factor: 19.112
Authors: Nasrin S Saiyed; Umar Yagoub; Bandar Al Qahtani; Attiya Mohammed Al Zahrani; Ibrahim Al Hariri; Meerab Javed Syed; Mohammed Elmujtaba Elmardi; Muhammad Abdullah Tufail; Marwan Manajreh Journal: J Multidiscip Healthc Date: 2022-07-27
Authors: Alexander Tamalunas; Amin Wendt; Florian Springer; Anna Ciotkowska; Beata Rutz; Ruixiao Wang; Ru Huang; Yuhan Liu; Heiko Schulz; Stephan Ledderose; Giuseppe Magistro; Christian G Stief; Martin Hennenberg Journal: Front Physiol Date: 2022-05-23 Impact factor: 4.755